ImmunityBio, Inc. (IBRX) - Stock Analysis
Last updated: Mar 8, 2026
Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
ImmunityBio posted ~700% YoY product-revenue growth, secured EU conditional approval and Saudi accelerated approval, and has multiple imminent clinical/label catalysts plus an investor update on 2026-03-03; the share price has climbed ~66% over 21 days and trades well above its 21âday SMA, positioning it as a highârisk but potent short-term momentum play.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠High gross margins ⢠Large cash burn ⢠Debt-heavy balance IBRX combines very high gross margins and healthy short-term liquidity with unsustainably high R&D-driven cash burn, large long-term debt, negative equity, and reliance on financing to continue operations.
Price Behavior
Key Price Behavior Insights: ⢠Short-term uptrend ⢠Rapid momentum ⢠Elevated volatility Support Level: $5.60â$6.10 Resistance Level: $10.40â$11.60 Price is in a clear short-term uptrend over the last month with strong momentum from an early-February base but elevated volatility from sharp spikes raises mean-reversion risk near support $5.60â$6.10 and resistance $10.40â$11.60.
Sentiment & News
Key News Insights: ⢠Regulatory approval ⢠Revenue surge ⢠Trial completion ImmunityBio's stock surged on EU conditional approval of Anktiva, dramatic revenue beats and completed pivotal trial enrollment, while persistent losses and insider/legal scrutiny keep risk high.
AI Summary
IBRX's rapid pivot from a preâcommercial biotech to an Anktivaâdriven commercial growth story materially reduces binary clinical risk but makes the investment outcome hinge on flawless commercial execution and nearâterm cashâflow/financing (sales ramp, payer reimbursement, and debt servicing). Monitor weekly/monthly Anktiva revenue trends, key payer coverage decisions, and covenant/debt maturity timelinesâany slowdown in uptake or reimbursement concessions will likely force dilutive financing and rapidly compress the richly priced valuation.
Description
ImmunityBio, Inc. is a clinical-stage biotechnology company developing therapies and vaccines targeting cancers and infectious diseases. The company applies multiple immunotherapy and cell therapy approachesâincluding engineered cytokine fusion proteins, synthetic immunomodulators, and both natural killer and T-cell platformsâand has candidates in Phase II/III trials for solid and liquid tumors (for example, bladder, pancreatic and lung cancers) as well as antiviral programs for pathogens such as SARS-CoV-2 and HIV. It maintains research collaborations and licensing arrangements with U.S. government institutes and several biopharma partners and is headquartered in San Diego, California.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Mar 2 | Mar 9 | IBRX | ImmunityBio, Inc. | ImmunityBio posted ~700% YoY product-revenue growth, secured EU conditional approval and Saudi accelerated approval, and has multiple imminent clinical/label catalysts plus an investor update on 2026-03-03; the share price has climbed ~66% over 21 days and trades well above its 21âday SMA, positioning it as a highârisk but potent short-term momentum play. | Closed | -19.1% |
| Feb 19 | Feb 26 | IBRX | ImmunityBio, Inc. | Multiple recent regulatory wins (EU conditional approval for ANKTIVA+BCG on 2026-02-18, Saudi approval, FDA Type B meeting) plus an EU commercialization deal and accelerating product revenue (~$38M quarter) have driven a >200% month-long rally; momentum remains strong into further catalyst and financing headlines despite high risk. | Closed | +10.9% |
| Jan 16 | Jan 23 | IBRX | ImmunityBio, Inc. | ImmunityBio is a hot idea driven by accelerating commercial revenue growth (700% annual increase in 2025), regulatory approvals expanding markets, positive clinical data mid-January 2026, nearly doubled stock price in past month, despite ongoing financial risks. | Closed | +16.9% |